Q2 2025 Rapid Micro Biosystems Inc Earnings Call Transcript
Key Points
- Rapid Micro Biosystems Inc (RPID) announced a new $45 million 5-year term loan facility with Trinity Capital, which supports their long-term strategy and reinforces their ability to achieve positive cash flow.
- Total revenue increased by 10% year-over-year to $7.3 million, with mid- to high-teens growth in consumables and service.
- Recurring revenue increased by 15%, indicating strong customer retention and ongoing demand for their products.
- Gross margins improved by 7 percentage points from the prior year, marking the fourth consecutive quarter of positive gross margins.
- The partnership with MilliporeSigma is progressing well, with joint commercial opportunities and initiatives to lower product costs and enhance supply chain efficiency.
- There is ongoing uncertainty around the timing and scale of customer purchase decisions, particularly for larger capital investments, due to global trade dynamics.
- Product margins were negative 11% in the quarter, impacted by one fewer system placement and revenue mix between systems and consumables.
- Operating expenses were $12.4 million, representing a decrease of only 6% from the previous year, indicating limited cost reduction.
- Net loss was $11.9 million in Q2, slightly improved from the previous year but still significant.
- The company expects to finish the year towards the low end of their previous guidance range for system placements, reflecting ongoing market challenges.
Good day, and thank you for standing by. Welcome to the Rapid Micro Biosystems second quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mike Boller, with Investor Relations. Please go ahead.
Good morning, and thank you for joining the Rapid Micro Biosystems second quarter 2025 earnings call. Joining me on the call are Rob Spignesi, President and Chief Executive Officer; and Sean Wirtjes, Chief Financial Officer. Earlier today, we issued two press releases. The first announcing a new $45 million 5-year term loan facility with Trinity Capital and the second announcing our Q2 2025 financial results.
Copies of both releases are available on the company's website at rapidmicrobio.com under Investors in the News and Events section. Before we begin, I'd like to remind you that many statements made during this call may be considered forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
